IDEAS home Printed from https://ideas.repec.org/a/pal/gpprii/v48y2023i3d10.1057_s41288-023-00302-z.html
   My bibliography  Save this article

COVID-19 off-label uses of medicines: the role of civil liability and regulation

Author

Listed:
  • Andrea Parziale

    (Maastricht University)

Abstract

Physicians can prescribe medicines for different indications than the tested and authorised ones. Such ‘off-label’ uses expand therapeutic options but also create uncertainties. The COVID-19 pandemic triggered new off-label uses and, despite issues being reported in the literature, these have not resulted in substantial personal injury litigation in the EU. Against this backdrop, this article argues that civil liability plays, in fact, a limited role in off-label uses. In particular, civil liability may incentivise health actors to follow and react to the development of the evidence basis for off-label uses. However, it is ultimately unable to incentivise the conduct of additional research on off-label uses. This is problematic, as off-label research is key to protecting patients and is recommended by international medical ethics. The article concludes by critically discussing proposed mechanisms to incentivise off-label research. It argues that extending civil liability for unknown risks may have undesired effects on insurability and innovation, and most regulatory proposals seem ineffective. Building on the 2014 Italian reform of off-label uses, the article proposes the establishment of a fund financed by mandatory contributions from the industry, which should be used by pharmaceutical regulators to promote off-label research and develop guidelines for prescribers.

Suggested Citation

  • Andrea Parziale, 2023. "COVID-19 off-label uses of medicines: the role of civil liability and regulation," The Geneva Papers on Risk and Insurance - Issues and Practice, Palgrave Macmillan;The Geneva Association, vol. 48(3), pages 669-686, July.
    • Handle: RePEc:pal:gpprii:v:48:y:2023:i:3:d:10.1057_s41288-023-00302-z
    DOI: 10.1057/s41288-023-00302-z
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1057/s41288-023-00302-z
    File Function: Abstract
    Download Restriction: Access to full text is restricted to subscribers.
    File URL: https://libkey.io/10.1057/s41288-023-00302-z?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Nabarun Dasgupta, 2021. "Safety Consequences of Off-Label Drugs Used for COVID-19," Drug Safety, Springer, vol. 44(4), pages 399-402, April.
    2. Carmen-Maria Rusz & Bianca-Eugenia Ősz & George Jîtcă & Amalia Miklos & Mădălina-Georgiana Bătrînu & Silvia Imre, 2021. "Off-Label Medication: From a Simple Concept to Complex Practical Aspects," IJERPH, MDPI, vol. 18(19), pages 1-15, October.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.

      Corrections

      All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:pal:gpprii:v:48:y:2023:i:3:d:10.1057_s41288-023-00302-z. See general information about how to correct material in RePEc.

      If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

      If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

      If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

      For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.palgrave-journals.com/ .

      Please note that corrections may take a couple of weeks to filter through the various RePEc services.

      IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.